VELscope System Named One of Top 100 Products for Third Consecutive Year
Fluorescence Visualization-Based Technology Is a Hit with Both Practices and Patients
WHITE ROCK, British Columbia—June 3, 2009—LED Dental Inc. announced today that its VELscope system was named one of Top 100 Products of 2009 by Dentistry Today.
Ralph Green, D.D.S., M.B.A., president and CEO of LED Dental’s parent, LED Medical Diagnostics, said, “When you consider that there are over 50,000 products in the dental industry, to be named one of the top 100 products for three consecutive years is quite an honor.”
Since its introduction, over 4,500 systems have been sold worldwide, and over 4.5 million VELscope examinations have been conducted. LED Dental estimates that over 3 million examinations will be conducted in 2009 alone.
The tissue fluorescence visualization technology platform on which the VELscope system is based is the culmination of over $50 million in research funded by the National Institutes of Health and other respected institutions and conducted by such leading organizations as the British Columbia Cancer Agency and the University of Texas’s M.D. Anderson Cancer Center. The VELscope system also helps clinicians discover precancerous lesions and many other types of oral mucosal abnormalities.
Independent surveys of dental practices using the VELscope system indicate extremely high satisfaction among clinicians and patients alike. Clinicians report satisfaction levels of 90% and higher for the VELscope system’s ability to detect lesions that otherwise would have been missed, for ease of incorporation into the practice, and for patient comfort and convenience. Surveys also indicate that VELscope exams take only 2-to-3 minutes, and that patients appreciate the fact that no distasteful rinses or messy dyes are involved. Moreover, the exams are considered affordable by the vast majority of patients and can be financially beneficial to the practice. Said Dr. Green, “This impressive feedback is a clear indication that every dental practice should have a VELscope system.” In fact, he points out, several customers have added a second system to their practice.
“Our mission is to help reduce the mortality rate of oral cancer by 70%, which is approximately the impact on cervical cancer mortality that is attributed to the Pap smear,” said Dr. Green. “We have a long way to go, but with the cooperation of dental practices who are willing to step up and act as the first line of defense against this disease, I am confident that we can get there.”
For more information, call +1 604 541-4614, or visit www.VELscope.com.
